Related Experiment Video
Updated: Mar 3, 2026

Enrichment of Native and Recombinant Extracellular Vesicles of Mycobacteria
Published on: December 8, 2023
Status of the development of a vaccine against Mycoplasma bovis
Jose Perez-Casal1, Tracy Prysliak1, Teresa Maina1
1Vaccine and Infectious Disease Organization - International Vaccine Centre - VIDO-InterVac, 120 Veterinary Rd, Saskatoon, Saskatchewan S7N 5E3, Canada.
Abstract:
Mycoplasma bovis is an important pathogen of cattle and, despite numerous efforts an effective vaccine for control of the disease it causes remains elusive. Although we now know more about the biology of this pathogen, information is lacking about appropriate protective antigens, the type of immune response that confers protection and adjuvants selection. The use of conserved recombinant proteins, selected using in silico approaches, as components of a vaccine may be a better choice over bacterin-based vaccines due to the limited protection afforded by them and adverse reactions caused by them. More studies are needed on the characterization of host-pathogen interactions and to elucidate M. bovis products modulating these interactions. These products could be the basis for development of vaccines to control M. bovis infections in dairy farms and feedlots.
More Related Videos
06:26Author Spotlight: Optimizing CFU Determination for Efficient Assessment of TB Vaccine Efficacy and Antigen Presentation Analysis
Published on: July 28, 2023
10:11Expression of Exogenous Antigens in the Mycobacterium bovis BCG Vaccine via Non-genetic Surface Decoration with the Avidin-biotin System
Published on: January 31, 2018
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Development of Antibiotic Resistance